Adelle Sutton
Family · Elizabethtown, KYNPI 1962872473
Payments from drug & device makers
Across 101 payments — averaging $15.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$551
- Pfizer$200
- Bayer$123
- Boehringer Ingelheim$118
- Phathom Pharmaceuticals, Inc.$91
- AbbVie$84
- plus $409 from 11 others
What the payments were for
- Food & beverage$1,576100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $551 |
| Pfizer | 16 | $200 |
| Bayer | 8 | $123 |
| Boehringer Ingelheim | 7 | $118 |
| Phathom Pharmaceuticals, Inc. | 5 | $91 |
| AbbVie | 5 | $84 |
| Lilly USA, LLC | 5 | $80 |
| Corcept Therapeutics | 4 | $77 |
| AstraZeneca | 2 | $44 |
| GSK | 3 | $43 |
| Amgen | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 2 | $28 |
| Radius Health, Inc. | 1 | $20 |
| Exact Sciences | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
How this compares
$1,576 in reported general payments places this provider in the 70th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 83 | $55,183 |
| EliquisApixaban | 38 | $38,849 |
| Nurtec OdtRimegepant Sulfate | 20 | $30,069 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $26,917 |
| OzempicSemaglutide | 17 | $15,985 |
| JanuviaSitagliptin Phosphate | 18 | $10,889 |
| LinzessLinaclotide | 17 | $8,808 |
| FarxigaDapagliflozin Propanediol | 15 | $8,527 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $7,881 |
| Repatha SureclickEvolocumab | 12 | $6,627 |
| TrintellixVortioxetine Hydrobromide | 14 | $5,540 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,620 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $3,144 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 72 | $1,885 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $1,788 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $200 | $68,91858 claims |
| Boehringer IngelheimJardiance | $118 | $55,18383 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $43 | $30,53647 claims |
| Novo NordiskOzempic | $551 | $15,98517 claims |
| AbbVieLinzess | $84 | $8,80817 claims |
| AstraZenecaFarxiga | $44 | $8,52715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,374 family providers in Kentucky.
Other family in Elizabethtown
- Ashley SnellenElizabethtown$190K
- Gwendolynn ThomasElizabethtown$12K
- Bonnie HillLouisa$372K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.